Biohaven Pharmaceutical (NYSE:BHVN) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $43.80 million-$43.80 million, compared to the consensus revenue estimate of $36.41 million.
A number of equities research analysts have recently weighed in on the stock. HC Wainwright dropped their price target on shares of Biohaven Pharmaceutical from $121.00 to $111.00 and set a buy rating for the company in a research report on Tuesday, January 19th. Morgan Stanley increased their target price on Biohaven Pharmaceutical from $73.00 to $76.00 and gave the stock an equal weight rating in a report on Monday, April 26th. Piper Sandler boosted their price target on Biohaven Pharmaceutical from $90.00 to $110.00 and gave the company an overweight rating in a research note on Monday, March 1st. Canaccord Genuity decreased their target price on shares of Biohaven Pharmaceutical from $110.00 to $101.00 and set a buy rating on the stock in a report on Tuesday, January 19th. Finally, William Blair reiterated a buy rating on shares of Biohaven Pharmaceutical in a research report on Friday, February 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Biohaven Pharmaceutical has a consensus rating of Buy and an average target price of $95.75.
NYSE:BHVN traded down $4.40 during trading hours on Tuesday, reaching $71.11. The stock had a trading volume of 562,555 shares, compared to its average volume of 616,525. The stock has a market cap of $4.41 billion, a P/E ratio of -6.15 and a beta of 1.09. The stock has a 50 day simple moving average of $71.84 and a 200 day simple moving average of $82.10. Biohaven Pharmaceutical has a 12-month low of $42.74 and a 12-month high of $100.77.
In other news, Director John W. Childs acquired 13,157 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, March 17th. The shares were purchased at an average cost of $76.00 per share, for a total transaction of $999,932.00. Also, Director John W. Childs bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 2nd. The stock was purchased at an average price of $85.14 per share, with a total value of $851,400.00. Following the transaction, the director now directly owns 2,532,644 shares in the company, valued at $215,629,310.16. The disclosure for this purchase can be found here. 19.10% of the stock is owned by insiders.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Further Reading: What is the NASDAQ Stock Market?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.